Sökning: onr:"swepub:oai:DiVA.org:uu-509446" > Syndecan-4 is a mae...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08583naa a2200697 4500 | |
001 | oai:DiVA.org:uu-509446 | |
003 | SwePub | |
008 | 230821s2023 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:e1d3d19e-f007-4245-a2bf-29e92cd240c3 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5094462 URI |
024 | 7 | a https://doi.org/10.1073/pnas.22148531202 DOI |
024 | 7 | a https://lup.lub.lu.se/record/e1d3d19e-f007-4245-a2bf-29e92cd240c32 URI |
040 | a (SwePub)uud (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Pocas, Julianau Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.,University of Porto4 aut |
245 | 1 0 | a Syndecan-4 is a maestro of gastric cancer cell invasion and communication that underscores poor survival |
264 | 1 | b Proceedings of the National Academy of Sciences (PNAS),c 2023 |
338 | a electronic2 rdacarrier | |
520 | a Gastric cancer is a dominating cause of cancer-associated mortality with limited therapeutic options. Here, we show that syndecan-4 (SDC4), a transmembrane pro-teoglycan, is highly expressed in intestinal subtype gastric tumors and that this sig -nature associates with patient poor survival. Further, we mechanistically demonstrate that SDC4 is a master regulator of gastric cancer cell motility and invasion. We also find that SDC4 decorated with heparan sulfate is efficiently sorted in extracellular vesicles (EVs). Interestingly, SDC4 in EVs regulates gastric cancer cell-derived EV organ distribution, uptake, and functional effects in recipient cells. Specifically, we show that SDC4 knockout disrupts the tropism of EVs for the common gastric cancer metastatic sites. Our findings set the basis for the molecular implications of SDC4 expression in gastric cancer cells and provide broader perspectives on the development of therapeutic strategies targeting the glycan-EV axis to limit tumor progression. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a syndecan-4 | |
653 | a heparan sulfate proteoglycans | |
653 | a gastric cancer | |
653 | a vesicles | |
653 | a cancer cell invasion | |
700 | 1 | a Marques, Catarinau Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Gomes, Catarinau Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Otake, Andreia Hanadau Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Canc Estado Sao Paulo, BR-01246000 Sao Paulo, Brazil.;Champalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal.4 aut |
700 | 1 | a Pinto, Filipeu Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Ferreira, Marianau Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Silva, Tiagou Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Faria-Ramos, Isabelu Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Matos, Ritau Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Ribeiro, Ana Raquelu Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Senra, Emanuelu Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Cavadas, Brunou Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Batista, Silviau Champalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal.4 aut |
700 | 1 | a Maia, Joanau Champalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal.4 aut |
700 | 1 | a Macedo, Joana A.u Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Lima, Luisu Portuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO)4 aut |
700 | 1 | a Afonso, Luis Pedrou Portuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO)4 aut |
700 | 1 | a Ferreira, José Alexandreu Portuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO)4 aut |
700 | 1 | a Santos, Lúcio Larau Portuguese Oncol Inst Porto IPO Porto, Res Ctr IPO Porto CI IPOP RISE CI IPOP, Hlth Res Network, Expt Pathol & Therapeut Grp, P-4200072 Porto, Portugal.,Instituto Português de Oncologia do Porto Francisco Gentil (IPO)4 aut |
700 | 1 | a Polónia, Antóniou University of Porto4 aut |
700 | 1 | a Osório, Hugou Univ Porto, FMUP Fac Med, P-4200319 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Belting, Mattiasu Uppsala University,Lund University,Lunds universitet,Uppsala universitet,Neuroonkologi och neurodegeneration,Science for Life Laboratory, SciLifeLab,Lund Univ, Dept Clin Sci, Sect Oncol, S-22184 Lund, Sweden; Skane Univ Hosp, S-22185 Lund, Sweden,Tumörmikromiljön,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Tumor microenvironment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)medk-mbe |
700 | 1 | a Reis, Celso A.u Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.;Univ Porto, FMUP Fac Med, P-4200319 Porto, Portugal.,University of Porto4 aut |
700 | 1 | a Costa-Silva, Brunou Champalimaud Fdn, Champalimaud Physiol & Canc Programme, P-1400038 Lisbon, Portugal.4 aut |
700 | 1 | a Magalhães, Anau Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.,University of Porto4 aut |
710 | 2 | a Univ Porto, i3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal.;Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P-4200465 Porto, Portugal.;Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4050313 Porto, Portugal.b University of Porto4 org |
773 | 0 | t Proceedings of the National Academy of Sciences of the United States of Americad : Proceedings of the National Academy of Sciences (PNAS)g 120:20q 120:20x 0027-8424x 1091-6490 |
856 | 4 | u https://doi.org/10.1073/pnas.2214853120y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1789859/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1073/pnas.2214853120x freey FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-509446 |
856 | 4 8 | u https://doi.org/10.1073/pnas.2214853120 |
856 | 4 8 | u https://lup.lub.lu.se/record/e1d3d19e-f007-4245-a2bf-29e92cd240c3 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy